Time From Diagnosis to Chemotherapy Initiation Is Not Associated with Survival Among Patients Receiving Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Neoadjuvant chemotherapy (NAC) is being utilized more frequently in patients with pancreatic adenocarcinoma (PDAC). Not all patients can tolerate modern multiagent regimens due to toxicity profiles or pre-existing comorbidities. We utilized institutional data and the National Cancer Database (NCDB) to investigate if the time from diagnosis to NAC start is associated with survival from surgery for PDAC.

https://www.journalacs.org/article/S1072-7515(21)01581-7/fulltext?rss=yes

Source: Journal of the American College of Surgeons - October 22, 2021 Category: Surgery Authors: Jonathan J. Hue, Kavin Sugumar, Luke Rothermel, John B. Ammori, Jeffrey M. Hardacre, Jordan M. Winter, Lee M. Ocuin Tags: Hepatobiliary and Pancreas Source Type: research